A prospective safety-monitoring study of immunotherapy in mite-allergy patients with mass-units-standardized extract

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 52, Issue 5, 1997, Pages 580-583

  Gonzalez De La Cuesta C ^a   Feijoo, R ^a   Rico, P ^b  

^a Allergology Section   (Spain)

^b ALK ABELLÓ   (Denmark)

Author keywords

Asthma; Dermatophagoides pteronyssinus; Immunotherapy; Major allergens; Rhinitis; Side effects

Indexed keywords

ALUMINUM HYDROXIDE; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; HOUSE DUST ALLERGEN; PANGRAMIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; DESENSITIZATION; DOSE RESPONSE; DRUG MONITORING; DRUG SAFETY; FEMALE; HOUSE DUST ALLERGY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PERENNIAL RHINITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; STANDARDIZATION; TOPICAL DRUG ADMINISTRATION;

EID: 0005579521     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1997.tb02604.x     Document Type: Article

References (15)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572.
2. Committee on Safety of Medicines update. Desensitizing vaccines. BMJ 1986;293:948.
3. Immunotherapy. Position paper. EAACI Immunotherapy Subcommittee. Allergy 1993;48 Suppl 14:9-35.
4. Tahar AI, García BE, Rodriguez A, Olaguihel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993;48:450-3.
5. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709-22.
6. Olaguibel JM, Tabar AI, Garcia Figueroa BE, Cortés C. Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose titration study. Allergy 1997;52:168-78.
7. Asthma International Consensus. National Heart, Lung, and Blood Institute, National Institutes of Health, Publication 92-3091, March 1992.
8. Lombardero M, González R, Duffort O, et al. Evaluación de la activtdad biológica total y composición alergénica de extratos alergénicos. Allergol Immunopathol (Madr) 1986;14:189.
9. Ventas R Lombardero M, Duffort O, Carreira J. Cuantificación de los alergenos Der p 1 y Der f 1 de los ácaros del polvo doméstico y Fel d 1 de gato, mediante un ELISA en fase sólida. Rev Esp Alergol Inmunol Clin 1990;5:71.
10. Circular 8/88. Dirección General de Farmacia y Productos Sanitarios. Ministerio de Sanidad y Consumo, 1988.
11. Badan M, Fasel-Felley J, Kolly M, Frei PC, Pécoud A. A prospective study of the undesirable effects of allergic desensitization. Schweiz Med Wochenschr 1986;116:243-5.
12. Greenberg MA, Kaufman CR, Gonzalez GE, Truswych ZR, Rosenblatt CD, Summers RJ. Late systemic-allergic reactions to inhalant allergen IT. J Allergy Clin Immunol 1988; 82:287-90.
13. Horak F. Pangramin-Praxisstudie: Nebenwirkungen und Therapieerfolg unter einer Hyposensibilisierung mit standardisierten Allergenen. Allergologie 1988;11:112-19.
14. Salamino F, Incidenza di reazioni avverse in corso di immunoterapia specifica. Lotta contro la TBC e malattie polmonari soc 1992;62:323-5.
15. Vervloet D, Khairallah A, Arnaud A. Charpin J. A prospective national study of the safety of IT. Clin Allergy 1980; 10:59-64.